Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II cisplatin + everolimus for extrapulmonary neuroendocrine carcinoma
2014-004735-39Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and everolimus in neuroendocrine carcinoma (NEC) and Merkel cell carcinoma (MCC), sponsored by Netherlands Cancer Institute. Primary endpoint: Disease control rate. Started Oct 2015; status: active.
02
Drugs
cisplatineverolimus
03
Conditions
neuroendocrine carcinoma (NEC)Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on 2014-004735-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004735-39.